BioNTech (NASDAQ:BNTX) Price Target Increased to $98.00 by Analysts at TD Cowen

BioNTech (NASDAQ:BNTX) had its price target lifted by TD Cowen from $95.00 to $98.00 in a research report released on Tuesday, Benzinga reports. The firm currently has a hold rating on the stock.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright reissued a buy rating and issued a $107.00 price objective on shares of BioNTech in a report on Wednesday, April 17th. Canaccord Genuity Group reiterated a buy rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. JPMorgan Chase & Co. reduced their price objective on BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research note on Friday, March 22nd. The Goldman Sachs Group lowered their target price on BioNTech from $113.00 to $100.00 and set a neutral rating on the stock in a research report on Wednesday, February 28th. Finally, UBS Group reduced their price target on BioNTech from $110.00 to $101.00 and set a neutral rating for the company in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has an average rating of Hold and an average price target of $118.27.

BioNTech Price Performance

Shares of BNTX opened at $90.88 on Tuesday. The firm has a fifty day simple moving average of $90.53 and a two-hundred day simple moving average of $95.99. The firm has a market cap of $21.60 billion, a PE ratio of 22.06 and a beta of 0.25. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. BioNTech has a 1-year low of $85.21 and a 1-year high of $125.83.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. On average, equities analysts anticipate that BioNTech will post -1.74 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of BioNTech by 6.9% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,711 shares of the company’s stock worth $186,000 after buying an additional 111 shares in the last quarter. Sectoral Asset Management Inc. increased its holdings in BioNTech by 3.5% in the 3rd quarter. Sectoral Asset Management Inc. now owns 3,445 shares of the company’s stock valued at $374,000 after acquiring an additional 116 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its stake in BioNTech by 2.5% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock worth $492,000 after purchasing an additional 116 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of BioNTech by 3.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 3,980 shares of the company’s stock valued at $432,000 after purchasing an additional 148 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.